Research record
Overview
Compound name: Tesamorelin
Alternative names: Egrifta (brand name)
Compound classification: Synthetic peptide; growth hormone–releasing hormone (GHRH) analog
Brief factual description:
Tesamorelin is a synthetic analog of growth hormone–releasing hormone designed to stimulate endogenous growth hormone secretion. It is clinically approved for specific metabolic indications and differs from other GHRH analogs by its regulatory status and defined clinical use.
Mechanism of Action
Primary biological targets: Growth hormone–releasing hormone receptors (GHRH-R) on pituitary somatotrophs
Affected systems: Endocrine, metabolic
Receptor selectivity: High specificity for GHRH receptors
Downstream signaling effects:
Increased pulsatile secretion of growth hormone, leading to secondary increases in IGF-1 and downstream metabolic signaling.
